Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Bezlotoxumab is marketed for the prevention of recurrent infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezlotoxumab in preventing rCDI and to investigate factors related to bezlotoxumab failure in the real world. A retrospective, multicentre cohort study of patients treated with bezlotoxumab in Spain was conducted. We compared the characteristics of cohort patients with those of patients treated with bezlotoxumab in the pivotal MODIFY trials. We assessed recurrence rates 12 weeks after completion of treatment against , and we analysed the factors associated with bezlotoxumab failure. Ninety-one patients were included in the study. The cohort presented with more risk factors for rCDI than the patients included in the MODIFY trials. Thirteen (14.2%) developed rCDI at 12 weeks of follow-up, and rCDI rates were numerically higher in patients with two or more previous episodes (25%) than in those who had fewer than two previous episodes of infection (CDI) (10.4%); = 0.09. There were no adverse effects attributable to bezlotoxumab. Despite being used in a more compromised population than that represented in clinical trials, we confirm the effectiveness of bezlotoxumab for the prevention of rCDI.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792623 | PMC |
| http://dx.doi.org/10.3390/jcm10010002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bezlotoxumab as Treatment for Recurrent/Chronic Clostridioides difficile Infection in Pediatric Stem Cell Transplant Recipients: A Multi-Institutional Experience.
Pediatr Blood Cancer
October 2025
Division of Pediatrics, Pediatric Hematology/Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Clostridioides difficile infection (CDI) represents a significant health risk to pediatric stem cell transplant (SCT) patients. In these patients, recurrent CDI is common, requiring prolonged antibiotic usage and increased hospitalization. Bezlotoxumab, a monoclonal antibody that targets the toxin responsible for CDI, has demonstrated efficacy in adult studies and was recommended for the prevention of recurrent CDI in the adult population.
View Article and Find Full Text PDFEpitope conservation of AZD5148, a broadly neutralizing anti-Toxin B monoclonal antibody, among diverse and global contemporary Clostridioides difficile isolates.
J Infect Dis
August 2025
Bioinformatics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Background: C. difficile Toxin B is a virulence factor for C. difficile infections (CDI), and a clinically validated target for prevention of CDI recurrence.
View Article and Find Full Text PDFMaking Sense of Differing Guidelines for Clostridioides difficile Infection.
Infect Dis Clin North Am
August 2025
Leeds Institute of Medical Research, Leeds Teaching Hospitals, University of Leeds, Leeds Ls1 3EX, UK.
The Clostridioides difficile infection (CDI) epidemic has been impacting the world for years. Understanding accurate diagnostics is imperative to allow the appropriate patients to be treated and improve outcomes. This article leverages multiple global societal guidelines to focus on the evolving diagnostic tests available summarizing best diagnostic practices including 2-step diagnostic testing.
View Article and Find Full Text PDFClinician Management Preferences for Infection in Adults: A 2024 Emerging Infections Network Survey.
Open Forum Infect Dis
July 2025
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Background: The 2021 Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines for infection (CDI) introduced new recommendations for managing initial and recurrent CDI. Since then, new microbiome-based therapies for preventing recurrent CDI have become available. We surveyed infectious diseases (ID) clinicians to understand their experiences, practices, and challenges in CDI management.
View Article and Find Full Text PDFReal-world use of bezlotoxumab to prevent recurrent infections: a single-center experience and meta-analysis.
Therap Adv Gastroenterol
June 2025
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Background: infection (CDI) treated with bezlotoxumab (BEZ) has been demonstrated to have a lower recurrence rate than placebo in clinical trials. However, real-world data on BEZ's effectiveness remain limited and heterogeneous.
Objectives: To evaluate the real-world effectiveness of BEZ in preventing CDI recurrence through a single-center retrospective cohort and a meta-analysis.